|
gptkbp:instance_of
|
gptkb:biotechnology
|
|
gptkbp:acquisition
|
gptkb:none
|
|
gptkbp:advances
|
CRISPR/ Cas9 improvements
|
|
gptkbp:annual_report
|
publicly available
|
|
gptkbp:business_model
|
biopharmaceutical development
|
|
gptkbp:can_lead_to
|
gptkb:NTLA-2001
|
|
gptkbp:ceo
|
gptkb:John_Leonard
|
|
gptkbp:clinical_trial
|
gptkb:NTLA-2001
gptkb:pharmaceuticals
ongoing
Phase 1
multiple phases
various sites
promising outcomes
ongoing recruitment
|
|
gptkbp:collaboration
|
gptkb:University_of_California,_Berkeley
gptkb:MIT
advancing gene editing therapies
|
|
gptkbp:collaborations
|
gptkb:Harvard_University
academic institutions
international partnerships
biotech firms
|
|
gptkbp:community
|
active participation
|
|
gptkbp:community_engagement
|
patient advocacy groups
|
|
gptkbp:focus
|
CRISPR gene editing
|
|
gptkbp:focus_area
|
oncology
|
|
gptkbp:founded
|
gptkb:2014
|
|
gptkbp:founder
|
gptkb:Jennifer_Doudna
|
|
gptkbp:funding
|
government grants
diverse funding sources
multiple successful rounds
|
|
gptkbp:future_plans
|
expand clinical trials
|
|
gptkbp:future_prospects
|
new therapeutic areas
|
|
gptkbp:has_advisory_board
|
composed of experts
|
|
gptkbp:headquarters
|
gptkb:Cambridge,_Massachusetts
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Intellia Therapeutics
|
|
gptkbp:initiatives
|
innovative projects
|
|
gptkbp:instruction_set
|
gptkb:NTLA-2002
|
|
gptkbp:invention
|
gptkb:CRISPR_technology
strong portfolio
|
|
gptkbp:investment
|
gptkb:venture_capital
various venture capital firms
transparent communication
|
|
gptkbp:is_a_platform_for
|
in vivo gene editing
|
|
gptkbp:market_cap
|
approximately $1 billion
|
|
gptkbp:market_position
|
growing presence in biotech
|
|
gptkbp:marketing_strategy
|
global expansion
|
|
gptkbp:notable_technology
|
gene therapy innovations
|
|
gptkbp:partnership
|
gptkb:Regeneron_Pharmaceuticals
collaborative efforts
|
|
gptkbp:partnerships
|
multiple pharmaceutical companies
|
|
gptkbp:publications
|
numerous publications
|
|
gptkbp:regulatory_compliance
|
gptkb:FDA
FDA submissions
|
|
gptkbp:research
|
gene editing advancements
|
|
gptkbp:research_areas
|
gptkb:Fuchsia
genetic diseases
multiple candidates
|
|
gptkbp:research_focus
|
inherited diseases
|
|
gptkbp:social_responsibility
|
commitment to ethics
|
|
gptkbp:stock_exchange
|
gptkb:NASDAQ
|
|
gptkbp:stock_symbol
|
gptkb:NTLA
|
|
gptkbp:team
|
experienced professionals
|
|
gptkbp:technology
|
gptkb:CRISPR/_Cas9
|
|
gptkbp:technology_validation
|
peer-reviewed studies
|
|
gptkbp:treatment
|
improved health outcomes
|
|
gptkbp:uses_technology
|
therapeutic applications
|
|
gptkbp:bfsParent
|
gptkb:Jennifer_Doudna
|
|
gptkbp:bfsLayer
|
3
|